HCC at ESMO GI 2025: TACE plus IO, personalized biomarkers, & emerging therapies
Автор: VJOncology
Загружено: 2025-07-15
Просмотров: 78
Описание:
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, reviews recent advances in liver cancer treatment presented at ESMO GI 2025. Prof. Lam Chan highlights the TALENTACE trial (NCT047126430), which confirms that combining TACE with systemic therapy, particularly immunotherapy, improves progression-free survival. In addition, Prof. Lam Chan stresses the importance of routine tumor biopsies to understand biology and baseline biomarkers for personalized treatment development, mentioning highly exploratory treatments including HDAC inhibitors, PPAR-alpha inhibition, and beta-catenin targeted therapies, noting that while clinical data is immature, promising results are expected within 5-10 years. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
